SCYNEXIS Stock

SCYNEXIS Working Capital Turnover

The Working Capital Turnover of SCYNEXIS (SCYX) as of Aug 15, 2026 is 0.06. In the previous year, Working Capital Turnover was 1.63 — a change of -96.11% (lower).

Working Capital Turnover

0.06

YoY

-96.11%

Last updated:

Working Capital Turnover of SCYNEXIS is 2026 0.06 . Working Capital Turnover of SCYNEXIS was 2025 1.63 . It decreases by -96.11% lower compared to the previous year.
Access this data via the Eulerpool API

SCYNEXIS Stock analysis

What does SCYNEXIS do? SCYNEXIS Inc is a biopharmaceutical company that focuses on the discovery and development of novel therapeutics for serious infectious diseases and cancer. The company was founded in 2000 and is headquartered in New Jersey, USA. SCYNEXIS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCYNEXIS stock

Working Capital Turnover of SCYNEXIS is 0.06 in 2026.

Working Capital Turnover of SCYNEXIS changed from 1.63 to 0.06, representing a -96.11% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Working Capital Turnover SCYNEXIS since 2006 – with annual values, charts, and detailed analysis.

Working capital turnover measures how efficiently a company uses its working capital to generate revenue. Higher ratios indicate more efficient short-term asset utilization.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Working Capital Turnover's SCYNEXIS with sector peers and the industry average to assess whether it is attractive.

To evaluate Working Capital Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Working Capital Turnover.

Access this data via the Eulerpool API

Profitability — SCYNEXIS

All Key Metrics — SCYNEXIS